Substitute for PTO/SB/21 (07-06)"Transmittal Form"
Approved for use through 09/30/2006. OMB 0651-0031

		U. S. Patent and Trade	mark Office; U.S. DEPARTMENT OF COMMERCE	
TRANSMITTAL FORM		Application Number	10/723,434	
		Filing Date	November 26, 2003 Pingyu Zhong	
		First Named Inventor		
used for all correspondence after initial filing		Art Unit	1643	
used for all correspondence after initial filing)		Examiner Name	Parithosh K. Tungaturhi	
Total Number of Pages in This Submission	17	Attorney Docket Number	AX0001ID	

			Art Unit	1643	
used for all correspondence after initial filing)		Examiner Name	Parithosh K. Tungaturhi		
Total Number of Pages in This Submission		17	Attorney Docket Number	AX0001ID	
	ENCL	OSURES	(Check all that appl	v)	
Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Remarks - Statement Under 3		vert to a blication ney, Revocation respondence Address simer fund CD(s)	Appeal Communication to Bo of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Br Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
SIGNATU	RE OF A	PPLICAN	T, ATTORNEY, OR	AGENT	
Vame Patricia L. Chisholm			Registration No. (Attorney/Agent)		45,822
ignature Catrum L Cluder				Date	8/30/2006
CERTI I hereby certify that this correspondence			NSMISSION/MAILIN		

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: August 30, 2006 Typed or printed name Danielle L. Murante Signature Date August 30, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Pingyu Zhong, et al.

Serial No.:

10/723,434

Case No.: AX0001ID

Art Unit: 1643

Filed:

November 26, 2003

Examiner:

Parithosh K. Tungaturhi

For:

HUMANIZED ANTIBODIES AGAINST

VASCULAR ENDOTHELIAL GROWTH FACTOR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT REGARDING LOSS OF ENTITLEMENT TO SMALL ENTITY STATUS

Sir:

Pursuant to the notification requirement of 37 CFR §1.27(g), the undersigned hereby notifies the United States Patent and Trademark Office (USPTO) that the above-referenced patent application is no longer entitled to small entity status.

The loss of entitlement results from a merger between Abmaxis, and an acquisition company, which had the effect of creating a successor of Abmaxis that is a wholly-owned subsidiary of Merck & Co., Inc.

This statement is accompanied by an executed PTO/SB/80 appointing practicioners associated with Customer Number 000210 as attorneys to represent Abmaxis Inc. (a subsidiary of Merck & Co., Inc.) before the USPTO in connection with any and all patent applications. Accordingly, undersigned is a person identified in 37 CFR §1.33(b).

Respectfully submitted,

B١

Patricia Chisholm Reg. No. 45,822

Attorney for Applicant MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-5738

Date: August 30, 2006